



**Biocon Limited**  
20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

BIO/SECL/SG/2024-25/155

January 12, 2025

To The Manager, <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 <b>Scrip Code - 532523</b>	To The Manager, <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 <b>Scrip Symbol - Biocon</b>
--	---

Dear Sir/Madam,

**Subject: Notification to Stock Exchanges**

Please find enclosed the company statement titled **“U.S. FDA Classifies Biocon Biologics Site in Johor Bahru, Malaysia as Voluntary Action Indicated (VAI)”**.

The above information will also be available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

\_\_\_\_\_  
**Mayank Verma**  
**Company Secretary & Compliance Officer**  
**Membership No: ACS 18776**

Encl: as above

**NOTIFICATION TO STOCK EXCHANGE**

**COMPANY STATEMENT**

**U.S. FDA Classifies Biocon Biologics Site in Johor Bahru, Malaysia as  
Voluntary Action Indicated (VAI)**

***Bengaluru, Karnataka, India, January 12, 2025***

“The U.S. Food and Drug Administration (FDA) has classified Biocon Biologics’ Insulins facilities in Johor Bahru, Malaysia as Voluntary Action Indicated (VAI).

“This relates to the cGMP inspection conducted by the agency between September 15 – 27, 2024. The inspection scope had included several biologics manufacturing units comprising one (1) Drug Substance and one (1) Drug Product manufacturing units, one (1) Medical Device Assembly unit, one (1) Analytical Quality Control Laboratory, two (2) Microbiological Control Laboratories and two (2) Warehouses.

“Biocon Biologics remains committed to global standards of Quality and Compliance.”

*– Company Spokesperson*

*For more information: [seema.ahuja@biocon.com](mailto:seema.ahuja@biocon.com)*